Avidity Biosciences nos comparte:

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #AvidityBiosciences #AkariNoviembre

🔬✨La base de la adquisición es la plataforma de Conjugados de Oligonucleótidos con Anticuerpos (AOCs, por sus iniciales en inglés) de Avidity.

🔗Lee el artículo completo en el siguiente link: lnkd.in/e6e8HKXw

#TheAkariFoundation #DistrofiaMuscular #terapiasARN #Novartis #AvidityBiosciences

Novartis neemt Avidity Biosciences over voor 12 miljard dollar Key takeaways Farmaceutische gigant Novartis heeft plannen aangekondigd om het Amerikaanse biotechbedrijf Avidity Biosciences over te nemen voor maar liefst 12 miljard dollar (10,3 miljard euro) in contanten. De overname betekent een premie van 46 procent ten opzichte van de slotkoers van het Avidity-aandeel op vrijdag, waardoor het bedrijf gewaardeerd wordt op 72 dollar (61,9 […]

Novartis neemt Avidity Biosciences over voor 12 miljard dollar #Novartis #AvidityBiosciences #overname #biotechnologie #farmaceutisch

Novartis va acquérir Avidity Biosciences pour 12 milliards de dollars Principaux renseignements Le géant pharmaceutique Novartis a annoncé son projet d’acquérir la société biotechnologique américaine Avidity Biosciences pour 12 milliards de dollars (10,3 milliards d’euros) en espèces. Cette acquisition représente une prime de 46 pour cent par rapport au cours de clôture de l’action Avidity vendredi, valorisant l’entreprise à 72 dollars (61,9 euros) par action. […]

Novartis va acquérir Avidity Biosciences pour 12 milliards de dollars #Novartis #AvidityBiosciences #acquisition #biotech #pharmaceutique

#Novartis is poised to make one of its largest takeover deals in its history after agreeing to buy #RNA specialist #AvidityBiosciences in a deal that could be worth around $12 billion.

pharmaphorum.com/news/novarti...

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

#dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences

👉 Read More: DMDWarrioR.com

🔬Avidity Biosciences ha anunciado nuevos datos positivos sobre los participantes tratados continuamente con del- zota por un año en los ensayos EXPLORE44® y EXPLORE44-OLE™.

🔗Lee el artículo completo en el link: lnkd.in/edASguP7

#TheAkariFoundation #DistrofiaMuscularDeDuchenne #AvidityBiosciences

Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial With del-zota, normal dystrophin increased by 25% and creatine kinase decreased by 80%. Among exon 44 skipping therapies, the highest values ​​currently received have caused excitement. Unprecedented rapid reduction in creatine kinase (CK) to near normal levels maintained over 16 months of follow-up and 25% increase of normal in dystrophin production, reflecting sustained muscle fiber protection.

Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial

#dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences

👉 Read More: DMDWarrioR.com

Rumour mill says Novartis may want to buy Avidity Novartis has made an offer to acquire RNA therapeutic specialist Avidity Biosciences, according to an unconfirmed report.

#Novartis has made an offer to acquire #RNA therapeutic specialist #AvidityBiosciences, according to an unconfirmed report in the Financial Times.

pharmaphorum.com/news/rumour-...

Novartis weighs deal for biotech Avidity Biosciences, FT reports (Reuters) -Swiss drugmaker Novartis (SIX:NOVN) has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported on Wednesday, citing people familiar with the matter. Shares of Avidity rose 23% to $47.1. It has a market value of $4.6 billion, according to LSEG data. Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, the report said, in a move aimed at boosting the drugmaker’s pipeline of medicines targeting rare genetic disorders. The discussions were at an early stage, the report said, adding that the sources had cautioned that another suitor could emerge or talks could collapse. Avidity, which has been developing treatments for rare muscle disorders, is working with advisers to assess options, the people added. Novartis and Avidity declined to comment when contacted by Reuters. Del-zota, Avidity’s lead drug, is in early to mid-stage development as a potential treatment for a rare form of Duchenne muscular dystrophy. The company is also working on two other drugs for serious muscle diseases. Novartis has been actively striking deals in 2025 as it looks to bolster its drug pipeline and drive future growth. In February, Novartis agreed to acquire Anthos Therapeutics for $3.1 billion to enhance its cardiovascular portfolio. The company also struck a deal in April valued at up to $1.7 billion to acquire Regulus (NASDAQ:RGLS) Therapeutics, gaining access to an experimental treatment for a serious kidney disease. Additionally, last month Novartis partnered with Matchpoint Therapeutics in a deal worth up to $1 billion to develop oral medicines targeting several inflammatory conditions.

Click Subscribe #Novartis #Biotech #AvidityBiosciences #Pharmaceuticals #HealthcareInvestment

Avidity Biosciences stock soars on Novartis takeover approach report Investing.com -- Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical giant Novartis (NYSE:NVS) has approached the rare disease-focused biotech company about a potential takeover. According to the report, which cited unidentified people familiar with the matter, Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks. Avidity is reportedly working with advisers to assess its options. The discussions are said to be at an early stage, and there is no guarantee that a deal will materialize, according to the sources cited in the report. The news also lifted shares of Dyne Therapeutics (NASDAQ:DYN), a company operating in a similar space, which also jumped 18% on Wednesday. Novartis has been actively reshaping its portfolio in recent years, focusing on high-growth areas including rare diseases. Any potential acquisition of Avidity would align with this strategy, potentially strengthening Novartis’s position in the rare disease treatment market. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if NOVN is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #AvidityBiosciences #Novartis #StockMarket #Takeover #Investing

🔗Lee el artículo completo en el siguiente link: theakarifoundation-pr.org/blog/

Da clic en el link de nuestro perfil y visita nuestros BLOGS más recientes

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DMD #AvidityBiosciences #delzota #EXPLORE44 #EXPLORE44OLE #AkariJulio

📣 Avidity Biosciences Comunica:

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #AvidityBiosciences #delzota #EXPLORE44 #EXPLORE44OLE #somoselcorazóndeladistrofia #AkariJulio

Este evento fue un espacio de comunidad, aprendizaje y esperanza. Vernos, escucharnos y apoyarnos nos recuerda que no estamos solos en este camino.🤝💙

#SareptaTherapeutics #NSPharma #EdgewiseTherapeutics #PTCTherapeutics #CatalystPharmaceuticals #ITFTherapeutics #AvidityBiosciences

Del-zota es un tratamiento para individuos que viven con distrofia muscular Duchenne con mutaciones susceptibles a la omisión del exón 44.🧬

🔗Lee el artículo completo en el siguiente link: bit.ly/4jigws1

#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #AvidityBiosciences

Avidity Biosciences Prepares for Three Rare Muscle Disease Programs’ 2025 BLA Submission and Commercialization Avidity Biosciences, Inc., a biopharmaceutical company producing Antibody Oligonucleotide Conjugates (AOC) RNA therapies, announced its progress and goals for a transformative 2025. A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025. These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44), getting ready for several product launches in DMD44, myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD), and establishing a completely integrated, international business to support an expanding AOC pipeline in precision cardiology and neuromuscular diseases.

Avidity Biosciences Prepares for Three Rare Muscle Disease Programs’ 2025 BLA Submission and Commercialization

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #duchenne #gene #dna #avidity #aviditybiosciences #raredisease